Cellectis (CLLS) FCF Payout Ratio Growth (3y) (2018 - 2026)
Cellectis (CLLS) FCF Payout Ratio Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.12% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 8.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.91% |
| Sep 30, 2025 | 149.97% |
| Jun 30, 2025 | 82.11% |
| Mar 31, 2025 | -20.94% |
| Sep 30, 2024 | -49.90% |
| Jun 30, 2024 | 27.65% |
| Mar 31, 2024 | 5.64% |
| Sep 30, 2023 | 343.16% |
| Jun 30, 2023 | -73.00% |
| Mar 31, 2023 | -28.04% |
| Sep 30, 2022 | -26.83% |
| Jun 30, 2022 | -5.84% |
| Mar 31, 2022 | 40.54% |
| Sep 30, 2021 | 85.58% |
| Jun 30, 2021 | 31.69% |
| Mar 31, 2021 | 20.22% |
| Sep 30, 2020 | 82.39% |
| Jun 30, 2020 | 15.48% |
| Mar 31, 2020 | 59.17% |
| Sep 30, 2019 | -27.67% |